InvestorsObserver
×
News Home

Should You Buy Surface Oncology Inc (SURF) Stock on Monday?

Monday, May 22, 2023 01:18 PM | InvestorsObserver Analysts

Mentioned in this article

Should You Buy Surface Oncology Inc (SURF) Stock on Monday?

Surface Oncology Inc (SURF) stock has risen 33.33% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,bullish
Surface Oncology Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on SURF!

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With SURF Stock Today?

Surface Oncology Inc (SURF) stock has gained 13.58% while the S&P 500 has fallen -0.01% as of 1:05 PM on Monday, May 22. SURF is up $0.10 from the previous closing price of $0.74 on volume of 407,376 shares. Over the past year the S&P 500 has risen 5.48% while SURF has fallen -55.08%. SURF lost -$1.53 per share in the over the last 12 months. To screen for more stocks like Surface Oncology Inc click here.

More About Surface Oncology Inc

Surface Oncology Inc is a clinical-stage immuno-oncology company. It is developing new therapies that modify the spaces in and around tumors the tumor microenvironment to create conditions that support and sustain anti-tumor immune responses. The company's pipeline products are SRF231, SRF373, SRF617, and SRF388. Geographically, the activities are carried out through the region of the United States. Click Here to get the full Stock Report for Surface Oncology Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App